LX201
Sponsors
Lux Biosciences, Inc.
Conditions
Cornea TransplantCorneal DiseasesCorneal Graft RejectionCorneal Transplantation
Phase 3
Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk
TerminatedNCT00447187
Start: 2007-04-30End: 2010-11-30Updated: 2012-10-11
Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty
TerminatedNCT00447642
Start: 2007-04-30End: 2010-01-31Updated: 2012-10-11